Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review

K Patell, M Kurian, JA Garcia, P Mendiratta… - Expert Review of …, 2023 - Taylor & Francis
Introduction Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive
form of prostate cancer that no longer responds to traditional hormonal treatment alone …

[HTML][HTML] Application of Artificial intelligence in oncologic molecular PET-imaging: a narrative review on beyond [18F] F-FDG tracers-part I. PSMA, choline, and DOTA …

SA Mirshahvalad, R Eisazadeh… - Seminars in Nuclear …, 2024 - Elsevier
Artificial intelligence (AI) has evolved significantly in the past few decades. This thriving
trend has also been seen in medicine in recent years, particularly in the field of imaging …

Development of Alginate-Based Biodegradable Radioactive Microspheres Labeled with Positron Emitter through Click Chemistry Reaction: Stability and PET Imaging …

A Gupta, JY Park, H Choi, TH Choi… - Molecular …, 2024 - ACS Publications
Biodegradable radioactive microspheres labeled with positron emitters hold significant
promise for diagnostic and therapeutic applications in cancers and other diseases, including …

PSMA-based therapeutics for prostate cancer

PV Stamatakos, C Fragkoulis, A Leventi… - Expert Opinion on …, 2024 - Taylor & Francis
ABSTRACT Introduction The prostate cancer (PCa) consists the most frequently diagnosed
malignancy of urogenital system in males. Traditionally, treatment of localized PCa was …

The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter study

E Almuradova, M Seyyar, H Arak… - … Journal of Cancer, 2024 - Wiley Online Library
Metastatic castration‐resistant prostate cancer (mCRPC) remains a challenging condition to
treat despite recent advancements. This retrospective study aimed to assess the activity and …

[PDF][PDF] Therapeutic Challenges in Metastatic Castration-Resistant Prostate Cancer: A Case Study and Review of Prostate-Specific Membrane Antigen-Targeted …

S Moghrabi, R Al-Houwari, S Ruzzeh, A Al-Ibraheem… - Cureus, 2024 - cureus.com
Prostate cancer (PCa) is a leading cause of cancer-related deaths globally, with metastatic
castrationresistant prostate cancer (mCRPC) posing significant treatment challenges. This …

[PDF][PDF] Development of targeted radioimmunotherapy for osteosarcoma using a comparative oncology approach

CB Prabaharan - 2024 - harvest.usask.ca
This study sheds light on the potential of develo** targeted antibody-based therapies for
osteosarcoma (OS)-a malignant bone tumor that affects both canines and humans …

[HTML][HTML] Preclinical positron emission computed tomography of prolonged tumor growth after lutetium-177 prostate-specific membrane antigen treatment in xenograft …

OE Klementyeva, AA Lipengolts… - Russian Journal of …, 2023 - rjonco.com
BACKGROUND: New treatment methods of castration-resistant prostate cancer with
radionuclide therapy are needed. They will optimize personalized strategy for radionuclide …

[PDF][PDF] Lutesyum-177: Üretimi ve Radyofarmasötikleri

AA Akit - 2023 - nukleertipseminerleri.org
Öz Lutesyum-177 (Lu-177), uygun fiziksel özellikleri nedeniyle tedavi ve görüntüleme
olanağı sunduğu için Nükleer Tıpta son yıllarda çok kullanılmaya başlanmış bir …

Lutetium-177: Production and Radiopharmaceuticals

AA Akit - Nukleer Tıp Seminerleri, 2023 - search.proquest.com
Abstract Lutetium-177 (Lu-177) is being widely used in nuclear medicine due to its physical
properties suitable for therapy and imaging. In this review production methods, fundamental …